SUMAYAH JAMAL, M.D.
Dermatology in New York, NY
License number
New York 201210
Category
Osteopathic Medicine
Type
Dermatology
Address
Address
166 Fl., New York, NY 10010
Phone
(212) 229-0333
(646) 218-4133 (Fax)
(646) 218-4133 (Fax)
Personal information
See more information about SUMAYAH JAMAL at radaris.comName
Address
Phone
24 Gramercy Park S #3W, New York, NY 10003
24 Gramercy Park S #3-W, New York, NY 10003
New York, NY
166 5Th St, New York, NY 10010
24 Gramercy Park, New York, NY 10003
Organization information
See more information about SUMAYAH JAMAL at bizstanding.comSumayah Jamal MD,PHD
418 Lafayette St, New York, NY 10003
Industry:
Dermatologist
Phone:
(212) 473-2419 (Phone)
Sumayah Jamal
Sumayah Jamal MD
166 5 Ave, Fl5, New York, NY 10010
Categories:
Dermatology Physicians & Surgeons
Phone:
(212) 255-5399 (Phone)
Professional information
Head Dermatologist At Keris Dermatology, Pllc
Position:
Head Dermatologist at Keris Dermatology, PLLC
Location:
Greater New York City Area
Industry:
Medical Practice
Work:
Keris Dermatology, PLLC
-
Head Dermatologist
Education:
New York University School of Medicine 1987 - 1994
MD-PhD, Medicine, Biochemistry The Johns Hopkins University 1982 - 1986
BA, Biology
MD-PhD, Medicine, Biochemistry The Johns Hopkins University 1982 - 1986
BA, Biology
Interests:
Jiujitsu, Tai Chi
Dr. Sumayah Jamal, New York NY - MD (Doctor of Medicine)
Specialties:
Dermatology
Address:
Keris Dermatology
166 5Th Ave, New York 10010
(212) 229-0333 (Phone)
166 5Th Ave, New York 10010
(212) 229-0333 (Phone)
Certifications:
Dermatology, 1998
Awards:
Healthgrades Honor Roll
Languages:
English, French
Education:
Medical School
New York University School Of Medicine
Graduated: 1994
Columbia Presby Med Center
Graduated: 1995
Nyu School Med and Med Center
Graduated: 1998
New York University School Of Medicine
Graduated: 1994
Columbia Presby Med Center
Graduated: 1995
Nyu School Med and Med Center
Graduated: 1998
Sumayah Jamal, New York NY
Specialties:
Dermatology, Internal Medicine
Work:
Nyu Dermatologic Associates
418 Lafayette St, New York, NY 10003
418 Lafayette St, New York, NY 10003
Education:
New York University (1994)
Cancer Treatment With Endothelin Receptor Antagonists
US Patent:
7566452, Jul 28, 2009
Filed:
May 4, 1999
Appl. No.:
09/305084
Inventors:
Robert J. Schneider - New York NY, US
Sumayah Jamal - New York NY, US
Sumayah Jamal - New York NY, US
Assignee:
New York University - New York NY
International Classification:
A61K 39/395, A61K 38/00, G01N 33/53
US Classification:
4241561, 514 2
Abstract:
The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.
Cancer Treatment With Endothelin Receptor Antagonists
US Patent:
2013030, Nov 21, 2013
Filed:
Jul 24, 2013
Appl. No.:
13/949895
Inventors:
Sumayah Jamal - New York NY, US
Assignee:
New York University - New York NY
International Classification:
A61K 39/395, A61K 31/7088
US Classification:
4241741, 514 44 A, 435 613, 435 723
Abstract:
The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.
Cancer Treatment With Endothelin Receptor Antagonists
US Patent:
8597645, Dec 3, 2013
Filed:
Oct 6, 2011
Appl. No.:
13/267360
Inventors:
Robert Schneider - New York NY, US
Sumayah Jamal - New York NY, US
Sumayah Jamal - New York NY, US
Assignee:
New York University - New York NY
International Classification:
A61K 39/395, A61K 38/00
US Classification:
4241431, 4241561, 514 133, 514 161, 514 192, 514 194
Abstract:
The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.
Cancer Treatment With Endothelin Receptor Antagonists
US Patent:
8067000, Nov 29, 2011
Filed:
May 22, 2009
Appl. No.:
12/470589
Inventors:
Robert J. Schneider - New York NY, US
Sumayah Jamal - New York NY, US
Sumayah Jamal - New York NY, US
Assignee:
New York University - New York NY
International Classification:
A61K 38/00, A61K 39/395, A61P 35/00
US Classification:
4241431, 4241551, 514 133, 514 161, 514 192, 514 193, 514 194, 435 723
Abstract:
The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.